Shares of SenesTech Inc (NASDAQ:SNES) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price target of $2.50 for the company, according to Zacks. Zacks has also given SenesTech an industry rank of 76 out of 256 based on the ratings given to related companies.
Separately, ValuEngine cut shares of WideOpenWest from a “hold” rating to a “sell” rating in a report on Friday, June 28th.
Shares of SenesTech stock traded up $0.02 on Monday, hitting $1.33. The company had a trading volume of 9,676 shares, compared to its average volume of 244,471. The company has a market capitalization of $32.74 million, a price-to-earnings ratio of -2.14 and a beta of 1.77. SenesTech has a twelve month low of $0.55 and a twelve month high of $1.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.83 and a quick ratio of 2.76. The company has a 50-day simple moving average of $1.55.
SenesTech (NASDAQ:SNES) last announced its earnings results on Wednesday, May 15th. The company reported ($0.10) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). SenesTech had a negative net margin of 3,908.08% and a negative return on equity of 186.65%. The business had revenue of $0.02 million during the quarter. As a group, equities analysts predict that SenesTech will post -0.19 EPS for the current fiscal year.
An institutional investor recently raised its position in SenesTech stock. Virtu Financial LLC raised its stake in shares of SenesTech Inc (NASDAQ:SNES) by 87.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,447 shares of the company’s stock after buying an additional 26,322 shares during the period. Virtu Financial LLC owned about 0.24% of SenesTech worth $69,000 as of its most recent SEC filing. 7.73% of the stock is currently owned by hedge funds and other institutional investors.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Further Reading: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.